Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan predicts 'overdue re-rating' at Informa

(Sharecast News) - JPMorgan has reiterated its 'overweight' position on Informa, predicting a "overdue re-rating" for the events, digital products and academic research stock as earnings momentum improves over the coming years. In July, JPMorgan reinstated its positive stance on the shares following a period of restriction, giving the stock a 1,020p target price.

At the time, the bank highlighted potential steps for Informa's management over the next 24 months, including: a focus on organic growth; the potential disposal of academic research division Taylor & Francis; de-risking through deleveraging; and aligning remuneration to shareholder interests.

In a research note on Wednesday, JPMorgan said that, following recent discussions it has had with investors, shareholders are focused on: "a) the resiliency of the portfolio and ability to sustainably grow +5% through the cycle and b) the merits of a potential disposal of Taylor & Francis."

A 10-month trading update from Informa is expected in mid-November "where we will look for a reassuring update on forward bookings and visibility on 2026 [...] and reaffirmation of the FY25 guide to underpin growing confidence in the narrative", the bank said..

JPMorgan said it sees a "strong case for improving earnings momentum", with the bank predicting 10% growth in adjusted earnings per share between 2026 and 2028, which should drive the stock's re-rating to narrow its valuation discount to others in the sector.

Shares were up 0.2% at 865.8p by 1050 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.